The economic burden of HER2-targeted therapy among metastatic breast cancer patients

被引：1

作者：

Forero-Torres, Andres ^{[1
]}

Anupindi, Vamshi Ruthwik ^{[2
]}

Yeaw, Jason ^{[2
]}

DeKoven, Mitch ^{[2
]}

Feliciano, Joseph ^{[1
]}

Richhariya, Akshara ^{[1
]}

机构：

[1] Seattle Genet, Bothell, WA USA

[2] IQVIA, Falls Church, VA USA

来源：

CANCER RESEARCH | 2020年 / 80卷 / 04期

关键词：

D O I：

10.1158/1538-7445.SABCS19-P1-18-17

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1-18-17

引用

页数：3

共 50 条

[1] HER2-targeted therapy influences CTC status in metastatic breast cancer
Thomas M. Deutsch
Sabine Riethdorf
Carlo Fremd
Manuel Feisst
Juliane Nees
Chiara Fischer
Andreas D. Hartkopf
Klaus Pantel
Andreas Trumpp
Florian Schütz
Andreas Schneeweiss
Markus Wallwiener
Breast Cancer Research and Treatment, 2020, 182 : 127 - 136
[2] HER2-targeted therapy influences CTC status in metastatic breast cancer
Deutsch, Thomas M.
Riethdorf, Sabine
Fremd, Carlo
Feisst, Manuel
Nees, Juliane
Fischer, Chiara
Hartkopf, Andreas D.
Pantel, Klaus
Trumpp, Andreas
Schuetz, Florian
Schneeweiss, Andreas
Wallwiener, Markus
BREAST CANCER RESEARCH AND TREATMENT, 2020, 182 (01) : 127 - 136
[3] Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer
Zongbi Yi
Guohua Rong
Yanfang Guan
Jin Li
Lianpeng Chang
Hui Li
Binliang Liu
Wenna Wang
Xiuwen Guan
Quchang Ouyang
Lixi Li
Jingtong Zhai
Chunxiao Li
Lifeng Li
Xuefeng Xia
Ling Yang
Haili Qian
Xin Yi
Binghe Xu
Fei Ma
npj Breast Cancer, 6
[4] Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer
Yi, Zongbi
Rong, Guohua
Guan, Yanfang
Li, Jin
Chang, Lianpeng
Li, Hui
Liu, Binliang
Wang, Wenna
Guan, Xiuwen
Ouyang, Quchang
Li, Lixi
Zhai, Jingtong
Li, Chunxiao
Li, Lifeng
Xia, Xuefeng
Yang, Ling
Qian, Haili
Yi, Xin
Xu, Binghe
Ma, Fei
NPJ BREAST CANCER, 2020, 6 (01)
[5] A new HER2-targeted therapeutic option for pretreated patients with metastatic breast cancer
Banys-Paluchowski, M.
ONKOLOGE, 2020, 26 (06): : 561 - 563
[6] Healthcare Resource Use and Expenditures among Metastatic Breast Cancer Patients Treated with HER2-Targeted Agents
Meyer, Nicole
Hao, Yanni
Song, Xue
Shi, Nianwen
Johnson, William
Rogerio, Jaqueline Willemann
Yardley, Denise A.
INTERNATIONAL JOURNAL OF BREAST CANCER, 2014, 2014
[7] Predictors of exceptional response to first line HER2-targeted therapy for metastatic breast cancer
Morganti, Stefania
Li, Tianyu
Santos, Katheryn
Hughes, Melissa
Priedigkeit, Nolan
Li, Yvonne
Lipsyc-Sharf, Marla
Kirkner, Gregory
Files, Janet
Kasparian, Julie
Grant, Elizabeth
Gupta, Gunjan
Curigliano, Giuseppe
Tolaney, Sara
Cherniack, Andrew
Tayob, Nabihah
Lin, Nancy
Parsons, Heather
CANCER RESEARCH, 2024, 84 (09)
[8] Novel HER2-targeted therapies for HER2-positive metastatic breast cancer
Kunte, Siddharth
Abraham, Jame
Montero, Alberto J.
CANCER, 2020, 126 (19) : 4278 - 4288
[9] OUTCOMES OF PATIENTS WITH HER2-POSITIVE BREAST CANCER METASTATIC TO BRAIN TREATED WITH HER2-TARGETED SYSTEMIC THERAPY AND STEREOTACTIC RADIOSURGERY
Shumway, John
Torras, Marina
Reeder-Hayes, Katherine
Jolly, Trevor
Dees, Elizabeth
Ray, Emily
Muss, Hyman
Carey, Lisa
Shen, Colette
NEURO-ONCOLOGY, 2021, 23 : 41 - 41
[10] Impact of adjuvant trastuzumab on outcomes of HER2-positive breast cancer patients treated with HER2-targeted therapy in the metastatic setting
Murthy, Rashmi Krishna
Varma, Ankur
Mishra, Priyankana
Hess, Kenneth R.
Young, Elliana J.
Murray, James L.
Koenig, Kimberly Higginbotham
Green, Marjorie C.
Moulder, Stacy L.
Melhem-Bertrandt, Amal
Booser, Daniel J.
Valero, Vicente
Hortobagyi, Gabriel N.
Esteva, Francisco J.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)

← 1 2 3 4 5 →